Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor

J. U. Shin, J. H. Park, ByoungChul Cho, JuHee Lee

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Epidermal growth factor receptor (EGFR) inhibitors have been used as anticancer agents for the treatment of a variety of solid tumors. Related skin toxicities are the most common adverse effects and occur with all EGFR inhibitors. Several treatment approaches, such as antiseptic soaps, topical and oral antibiotics, and topical and oral corticosteroids, have been reported; however, the responses have been varied. Acneiform eruption induced by EGFR inhibitor treatment results from disturbed normal keratinocyte and hair follicle biology and may therefore benefit from local restoration of EGF pathway. Observations: We treated HaCaT cells with EGFR inhibitor and evaluated the expression of EGFR. After treatment of cells with EGFR inhibitor, EGFR expression was increased in a dose-dependent manner. We hypothesized that newly synthesized EGFR, not inhibited by EGFR inhibitors, may perform their biological action in keratinocytes in the presence of additional EGF. In this study, we therefore treated acneiform eruption patients with topical recombinant human EGF (rhEGF) with institutional review board approval. Here, we report three cases of such eruptions who responded to topical rhEGF. Conclusion: Topical rhEGF may be an effective treatment option for EGFR inhibitor-induced acneiform eruption.

Original languageEnglish
Pages (from-to)135-140
Number of pages6
JournalDermatology
Volume225
Issue number2
DOIs
Publication statusPublished - 2012 Nov 1

Fingerprint

Acneiform Eruptions
Epidermal Growth Factor Receptor
Epidermal Growth Factor
Therapeutics
Keratinocytes
Soaps
Local Anti-Infective Agents
Hair Follicle
Research Ethics Committees
Antineoplastic Agents

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

@article{d4723d0c3f2b455d84b328e2c9a192ec,
title = "Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor",
abstract = "Background: Epidermal growth factor receptor (EGFR) inhibitors have been used as anticancer agents for the treatment of a variety of solid tumors. Related skin toxicities are the most common adverse effects and occur with all EGFR inhibitors. Several treatment approaches, such as antiseptic soaps, topical and oral antibiotics, and topical and oral corticosteroids, have been reported; however, the responses have been varied. Acneiform eruption induced by EGFR inhibitor treatment results from disturbed normal keratinocyte and hair follicle biology and may therefore benefit from local restoration of EGF pathway. Observations: We treated HaCaT cells with EGFR inhibitor and evaluated the expression of EGFR. After treatment of cells with EGFR inhibitor, EGFR expression was increased in a dose-dependent manner. We hypothesized that newly synthesized EGFR, not inhibited by EGFR inhibitors, may perform their biological action in keratinocytes in the presence of additional EGF. In this study, we therefore treated acneiform eruption patients with topical recombinant human EGF (rhEGF) with institutional review board approval. Here, we report three cases of such eruptions who responded to topical rhEGF. Conclusion: Topical rhEGF may be an effective treatment option for EGFR inhibitor-induced acneiform eruption.",
author = "Shin, {J. U.} and Park, {J. H.} and ByoungChul Cho and JuHee Lee",
year = "2012",
month = "11",
day = "1",
doi = "10.1159/000342203",
language = "English",
volume = "225",
pages = "135--140",
journal = "Dermatology",
issn = "1018-8665",
publisher = "S. Karger AG",
number = "2",

}

Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor. / Shin, J. U.; Park, J. H.; Cho, ByoungChul; Lee, JuHee.

In: Dermatology, Vol. 225, No. 2, 01.11.2012, p. 135-140.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor

AU - Shin, J. U.

AU - Park, J. H.

AU - Cho, ByoungChul

AU - Lee, JuHee

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Background: Epidermal growth factor receptor (EGFR) inhibitors have been used as anticancer agents for the treatment of a variety of solid tumors. Related skin toxicities are the most common adverse effects and occur with all EGFR inhibitors. Several treatment approaches, such as antiseptic soaps, topical and oral antibiotics, and topical and oral corticosteroids, have been reported; however, the responses have been varied. Acneiform eruption induced by EGFR inhibitor treatment results from disturbed normal keratinocyte and hair follicle biology and may therefore benefit from local restoration of EGF pathway. Observations: We treated HaCaT cells with EGFR inhibitor and evaluated the expression of EGFR. After treatment of cells with EGFR inhibitor, EGFR expression was increased in a dose-dependent manner. We hypothesized that newly synthesized EGFR, not inhibited by EGFR inhibitors, may perform their biological action in keratinocytes in the presence of additional EGF. In this study, we therefore treated acneiform eruption patients with topical recombinant human EGF (rhEGF) with institutional review board approval. Here, we report three cases of such eruptions who responded to topical rhEGF. Conclusion: Topical rhEGF may be an effective treatment option for EGFR inhibitor-induced acneiform eruption.

AB - Background: Epidermal growth factor receptor (EGFR) inhibitors have been used as anticancer agents for the treatment of a variety of solid tumors. Related skin toxicities are the most common adverse effects and occur with all EGFR inhibitors. Several treatment approaches, such as antiseptic soaps, topical and oral antibiotics, and topical and oral corticosteroids, have been reported; however, the responses have been varied. Acneiform eruption induced by EGFR inhibitor treatment results from disturbed normal keratinocyte and hair follicle biology and may therefore benefit from local restoration of EGF pathway. Observations: We treated HaCaT cells with EGFR inhibitor and evaluated the expression of EGFR. After treatment of cells with EGFR inhibitor, EGFR expression was increased in a dose-dependent manner. We hypothesized that newly synthesized EGFR, not inhibited by EGFR inhibitors, may perform their biological action in keratinocytes in the presence of additional EGF. In this study, we therefore treated acneiform eruption patients with topical recombinant human EGF (rhEGF) with institutional review board approval. Here, we report three cases of such eruptions who responded to topical rhEGF. Conclusion: Topical rhEGF may be an effective treatment option for EGFR inhibitor-induced acneiform eruption.

UR - http://www.scopus.com/inward/record.url?scp=84870829158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870829158&partnerID=8YFLogxK

U2 - 10.1159/000342203

DO - 10.1159/000342203

M3 - Article

VL - 225

SP - 135

EP - 140

JO - Dermatology

JF - Dermatology

SN - 1018-8665

IS - 2

ER -